Meet our Partners and Collaborators
At InMed Pharmaceuticals, we’ve teamed up with vendors and collaborators who are world leaders in their respective fields and bring specific skill sets to our programs. This sharing of knowledge and capabilities supports our R & D efforts while helping to advance our cannabinoid manufacturing and therapeutic programs.
If you are interested in collaborating with InMed Pharmaceuticals or would like to learn more, contact us.
The University of British Columbia – Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences
The collaboration, entitled “Pharmacological characterization of phytocannabinoids and the endocannabinoid system” will investigate the potential therapeutic effects of selected rare cannabinoid analogs in neurodegenerative diseases.
Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed’s cannabinoid pharmaceutical candidates for neurodegenerative diseases.
Read about the study in this press release.
About the University of British Columbia
The University of British Columbia (UBC) is a global centre for teaching, learning and research, consistently ranked among the top 20 public universities in the world and recently recognized as North America’s most international university. https://www.ubc.ca/
University of L’Aquila (Italy), Department of Applied Clinical Sciences and Biotechnology, Dr. Mauro Maccarrone
InMed has initiated a research collaboration with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone, an international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance. He is also the 2007 recipient of the International Association for Cannabinoid Medicines’s prestigious Ester Fride Award for Basic Research, and the 2016 recipient of the International Cannabinoid Research Society’s prestigious Mechoulam Award. Dr. Maccarrone’s lab will be screening the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.
Stem Pharm
InMed is conducting INM-901 neuroinflammation studies in 3D human brain organoid models of Alzheimer’s disease in collaboration with Stem Pharm, Inc.
Stem Pharm’s proprietary drug discovery platform is based on human 3D neuro-immune organoids that feature microglia and model neuroinflammation, which play a critical role in many neurological diseases. The company applies this platform to discover and validate disease targets and therapeutics for its internal programs in Alzheimer’s disease, epilepsy, and brain cancer as well as for its biopharma partners’ therapeutic programs. Stem Pharm is based in Madison, WI, a hub for innovative stem cell and biosciences research. For more information, visit stempharm.com.